International urology and nephrology
Restricted mean survival time comparison of olaparib plus abiraterone versus talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer: indirect analyses of propel and talapro-2.
Yosuke Yasuda, Soichiro Yoshida, Shugo Yajima, Hiroyuki Sato, Akihiro Hirakawa, Yasuhisa Fujii
Published: 202510.1007/s11255-025-04951-y
No abstract available for this study.